Latest News

Community pharmacists are especially valuable amid lower interest and staff shortages.

Infectious disease experts provide the latest updates in RSV, pneumococcal disease, whooping cough, and multidrug-resistant tuberculosis.

New research reveals how menopausal hormone therapy impacts cognitive health in postmenopausal women, highlighting the importance of administration routes and estrogen types.

Overdoses remain alarmingly high despite new tools like OTC Naloxone, highlighting persistent barriers to care.

Experts outline innovative approaches to reduce inequities in diagnostic access and optimize patient outcomes.

As psychedelic medicines near approval, pharmacists will become essential guides in safety and education.

From embedded PrEP care to rapid outbreak response logistics, new models are showing how pharmacists can establish successful public health partnerships to enhance patient access and equity.

Elinzanetant was effective in women with low vasomotor symptom (VMS) burden and those with endocrine therapy-caused VMS.

Compared with late postmenopausal women, menopausal hormone therapy (MHT) may influence certain Alzheimer disease-related biomarkers in early postmenopausal women.

Although long COVID remains a complex disease, pharmacists are critical team members for patient symptom validation, managing polypharmacy, and navigating therapy access.

Increasing vaccine confidence demands that pharmacists move beyond simply sharing facts to utilizing effective communication strategies.

The FDA approves obinutuzumab (Gazyva; Genentech) for lupus nephritis, offering a new treatment option with improved renal outcomes for patients.

Pharmacists play a vital role in managing respiratory virus season by providing vaccinations, counseling, and recommending effective treatments for patients.

Long-term findings from the REASSURE study confirm Radium-223’s acceptable hematologic safety profile and reinforce the importance of early use alongside bone-protecting agents to minimize fracture risk and optimize outcomes.

Personalized cancer vaccines target tumor heterogeneity, enhancing immune responses and improving treatment outcomes in diverse cancer types.

Experts at ESMO 2025 highlight antibody-drug conjugates in HER2-positive metastatic breast cancer treatment.

Emerging biomarkers and targeted therapies are reshaping the landscape of lung cancer treatment and drug development.

Advances in targeted therapies, combination approaches, and novel treatment strategies are shaping the management of drug-resistant lung cancer.

Insights from ESMO 2025 highlight advancements in non-small cell lung cancer treatment, focusing on novel therapies and molecular diagnostics.

New data from the NATALEE trial reveals ribociclib significantly improves invasive disease-free survival in HR+/HER2– early breast cancer.